Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Important safety considerations include: Separate fiber supplements from medications : Take fiber supplements at least 2 hours apart from oral medications to avoid potential interference with absorption Monitor for obstruction symptoms : Severe abdominal pain, inability to pass gas, or vomiting requires immediate medical evaluation, as FDA labels for GLP-1 medications include rare postmarketing reports of intestinal obstruction (ileus) [1] [2] Coordinate with healthcare providers : Patients with inflammatory bowel disease, diverticulitis history, or other gastrointestinal conditions need individualized fiber recommendations Adjust fluid intake appropriately : Follow medical guidance if you have conditions requiring fluid restriction Patients should contact their healthcare provider if gastrointestinal symptoms persist despite dietary modifications, worsen significantly, or include warning signs such as blood in stool, unintentional weight loss beyond expected therapeutic effects, or severe abdominal pain
Li R, Qi J, Yang Y, Wu Y, Yin P, Zhou M, Qian Z, LeBaige MH, McMillin SE, Guo H, Lin H (2021) Disease burden and attributable risk factors of Alzheimers disease and dementia in China from 1990 to 2019
International journal of peptides
Founders in the GLP-1 space need to understand more than market size and regulation, they must understand how capital moves in this category
acknowledges the support of the Banting and Best Diabetes Centre Novo Nordisk Chair in Incretin Biology, the Sinai Health-Novo Nordisk Foundation Fund in regulatory peptides and CIHR grant number 154321
US$ 21.38
US$ 24.68
US$ 25.97
US$ 23.66
